Results 111 to 120 of about 418,673 (161)

A disproportionality analysis of insulin glargine in the overall population and in pregnant women using the FDA adverse event reporting system (FAERS) database. [PDF]

PLoS One
Liu S, Xu J, Yuan Z, Mei Z, Shi S, Yin J, Deng Y.   +6 more
europepmc   +1 more source

Once-weekly insulin icodec vs. daily insulin glargine in type 2 diabetes: a meta-analysis with longitudinal insights. [PDF]

Ann Med Surg (Lond)
Ashraf T, Kumar A, Tara A, Memon N, Muhammad A, Turesh M, Dev S, Muhammad N, Kumar V, Hussain T, Kumar R, Singh A, Bajaj S, Qammar A, Deepak F, Kumar A, Yusuf SA.   +16 more
europepmc   +1 more source

Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia. [PDF]

Indian J Crit Care Med
El Sherif IM, Haggag AM, Abbas MH, Kamel WY.   +3 more
europepmc   +1 more source

Role of biosimilar introduction on insulin glargine prices: a retrospective analysis in 28 European countries. [PDF]

BMJ Open
Morolla D, Beran D, Ewen M, Raviglione M, von Schoen-Angerer T.   +4 more
europepmc   +1 more source

Timing of Insulin Glargine 300 U/ML: Does It Really Matter in Terms of Efficacy and Safety at Insulin Initiation? [PDF]

Cureus
Sanyal D, Mitra A.
europepmc   +1 more source

Prescription Dispensing for Insulin Glargine After Interchangeable Biosimilar Designation.

JAMA Health Forum
Murphy SJ, Holtkamp NC.
europepmc   +1 more source

Management of diabetic ketoacidosis in children: Does early insulin glargine help improve outcomes? [PDF]

J Diabetes
Ohman-Hanson R, Alonso GT, Pyle L, McDonough R, Clements M.   +4 more
europepmc   +1 more source

The risk of cancer among insulin glargine users in Lithuania: A retrospective population-based study. [PDF]

Open Med (Wars)
Jonusas J, Drevinskaitė M, Linkeviciute-Ulinskiene D, Ladukas A, Patašius A, Zabulienė L, Smailytė G.   +6 more
europepmc   +1 more source

Pharmacokinetics, Pharmacodynamics, and Bioequivalence of Test Insulin Glargine Versus Reference Preparation (Lantus^®) in Healthy Male Volunteers-By Euglycemic Clamp Technique. [PDF]

Pharmaceutics
Li Z, Liu M, Tao Y, Wan L, Chen Y, Zhu M, Zhao H, Tang C.   +7 more
europepmc   +1 more source

An exploratory analysis of the cost-effectiveness of insulin glargine 300 units/mL versus insulin glargine 100 units/mL over a lifetime horizon using the BRAVO diabetes model. [PDF]

Diabet Med
Shao H, Shi L, Fonseca V, Alsaleh AJO, Gill J, Nicholls C.   +5 more
europepmc   +1 more source